DATROWAY Supplemental NDA Submitted in Japan for Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy
“Metastatic triple negative breast cancer is highly aggressive and has one of the worst prognoses of any subtype of breast cancer,” said Yuki Abe, PhD, Head of R&D Division in Japan and Head of Research, Daiichi Sankyo. “We are working as quickly as possible with the Japan health authority to make DATROWAY the first TROP2 directed antibody drug conjugate to become available in Japan for first-line triple negative breast cancer, addressing the unmet need for the seventy percent of patients in this setting who are not candidates for immunotherapy.”
Share:
More News
Dr. Michael Ge, CEO of Kelun-Biotech said, “We are delighted to see the acceptance of the fifth indication application for sac-TMT. Compared to immunotherapy alone, the ADC combination with KEYTRUDA® as first-line treatment for PD-L1-positive NSCLC has achieved not only positive results in PFS, but also a trend toward benefit
“We are excited to work with Merck to advance this promising investigational combination in RAS-driven cancers,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “RAS mutations activate the RAS/MAPK pathway and promote an immunosuppressive environment. Non-clinical data suggest that targeting the pathway with ERAS-0015 may complement PD-1 blockade
“Dosing the first patient in the ASPENOVA Phase 3 clinical trial represents a significant milestone in our development of azenosertib for patients with platinum-resistant ovarian cancer,” said Ingmar Bruns, M.D., Chief Medical Officer of Zentalis. “With DENALI Part 2 progressing toward a year-end readout that may support accelerated approval and
“The depth, durability, and consistency of responses observed across both the total population and BTKi-treated subsets underscore iopofosine’s potential as a meaningful new treatment option in WM and differentiate it from currently available therapies,” said Jarrod Longcor, chief operating officer of Cellectar Biosciences. “With the completion of at least 12-month